RVTY

Analyst Note: Revvity, Inc. (RVTY)

Date: June 20, 2026 Event Date: 2026-06-20

1. Structural Readiness

Current State: Forming Price Action: The stock is currently trading at $100.00, which is below the breakout threshold but holding above the critical support line.

• Conservative Entry: Not yet actionable (requires confirmed breakout).
• Aggressive Entry: $100.03 (Pre-breakout / Forming entry).
• Breakout Level: $118.30 (Resistance level that must be cleared to confirm the setup).
• Extension: None (Price is within the base range, not extended).
• ATR Context: Current ATR is 3.8% (productive). This volatility is within the historical "sweet spot" (4–6% is ideal, 3.8% is acceptable for sizing) and suggests the stock is active enough to move but not in an extreme volatility regime.

Classification: The setup is FORMING.

• Status: The coil is not invalidated. A close below $97.60 would invalidate the setup.

2. Thesis Layer

Primary Secular Theme: Biotech & GLP-1 → Platforms, Tools & CRO/CDMO. Directness: Tier Direct. Conviction Weighting: High.

Revvity is positioned as a direct beneficiary of the secular acceleration in drug discovery and development. The company operates as a critical infrastructure provider for the "AI-driven discovery" narrative. As artificial intelligence accelerates the generation of therapeutic hypotheses (as noted by management), the downstream demand for the laboratory tools, reagents, and instruments required to validate these discoveries is structurally increasing. Revvity's role is not merely as a service provider but as a platform enabler for the entire workflow from discovery to diagnosis.

3. Business Overview

Company Role: Revvity is a leading provider of health science solutions, technologies, and services delivering complete workflows from discovery to development, and diagnosis to cure. Business Model: The company operates through two primary segments:

• Diagnostics: Focused on reproductive health, immunodiagnostics, and emerging market diagnostics.
• Life Sciences: Focused on translational multi-omics, biomarker identification, imaging, and informatics.

Financial Performance (as of Q1 FY2026):

• Total Revenue: $711.1 million, up 7% year-over-year (YoY).
• Diagnostics Segment: Revenue increased 8% to $361.8 million (driven by $24.9M growth).
• Life Sciences Segment: Revenue increased 6% to $361.8 million (driven by $21.4M growth).
• Growth Drivers: The Life Sciences segment saw specific growth in Solutions revenue ($13.5M) and Software revenue ($7.9M), alongside the impact of an extra fiscal week.

Strategic Shifts: Management has announced a planned divestiture of the China Immunodiagnostics business.

• Impact on Growth: Management estimates this divestiture will negatively impact organic growth by excluding the business but will *improve* the reported organic growth rate by approximately 100 basis points (bps) for 2026 due to the exclusion of lower-growth or negative-growth components.
• Margin Impact: The divestiture is expected to enhance operating margins by approximately 30 bps.
• 2026 Guidance: Management is estimating 3% to 4% organic growth overall for 2026, excluding the China Immunodiagnostics business.

Cost Environment: Tariffs enacted and in effect increased cost of revenue by approximately $8 million in Q1 FY2026. Through proactive mitigation, the net impact on gross margin was limited to approximately $6 million. Consolidated gross margins decreased 200 bps to 54.5% in Q1 FY2026, primarily due to product mix shifts, foreign exchange rates, tariffs, and the extra fiscal week.

4. Archetype and Conviction

Archetype: Margin Inflector / Quality Compounder (Transitioning). Revvity fits the profile of a quality compounder undergoing a strategic optimization. The company is actively managing its portfolio to shed lower-margin or geographically constrained assets (China Immunodiagnostics) to improve the quality of its remaining revenue stream. The strategic pivot is designed to unlock margin expansion (targeting +30 bps) and improve the organic growth profile (+100 bps) by focusing on higher-growth Life Sciences and Software components.

Conviction Stack:

• Thesis Strength: High. The alignment with AI-driven drug discovery is a robust secular tailwind.
• Evidence Quality: Strong. Q1 FY2026 results show top-line resilience (7% growth) despite macro headwinds (tariffs, FX).
• Structural Quality: Moderate to High. The "Forming" coil structure suggests accumulation and a potential breakout, provided the $118.30 resistance is cleared.
• Rerating Potential: Moderate. The market may re-rate the stock as the divestiture closes and the margin benefits materialize, provided the "3-4% organic growth" guidance is met or exceeded.

Valuation Context:

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Breakout Confirmation: A daily close above $118.30 would confirm the coil structure and signal institutional accumulation.
• Margin Expansion: Confirmation that the divestiture has successfully improved margins by the targeted 30 bps in subsequent quarters.
• Software Growth: Continued double-digit growth in the Software segment, indicating successful monetization of the AI-driven discovery workflow.

What Would Invalidate the Case:

• Guidance Miss: A significant miss on the 3-4% organic growth guidance for 2026, particularly if driven by a slowdown in Life Sciences demand.
• Tariff Escalation: If tariffs increase beyond the current $8 million impact, eroding margins further than the 200 bps decline seen in Q1.

Gaps in Evidence:

• Divestiture Timeline: The specific closing date and final financial impact of the China Immunodiagnostics divestiture are not detailed in the provided evidence, only the *expected* impact.
• Full Year Margins: While Q1 gross margins are provided, the full-year margin trajectory post-divestiture is a management expectation, not a realized fact.
• AI Revenue Attribution: While management links AI to demand, the specific revenue contribution from AI-related products is not quantified in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: medium Key evidence: Q1 FY2026 revenue growth of 7% to $711.1M despite tariff headwinds; Management guidance for 3-4% organic growth excluding divested China business; Strategic pivot to higher-margin Life Sciences and Software segments. Key risks: Failure to clear $118.30 resistance level; Tariff escalation exceeding mitigation capabilities; Divestiture execution delays or lower-than-expected margin benefits. Expected path: Price consolidates near current levels while management executes the divestiture; potential for a breakout above $118.30 if Q2 results confirm margin expansion and growth trajectory. Expected horizon: 3 to 6 months for the structural setup to resolve (breakout or invalidation). Failure mode to watch: A daily close below $97.60, which would invalidate the forming coil structure and signal a breakdown in support.